Drug Profile
Coelenterazine
Latest Information Update: 20 Jul 1999
Price :
$50
*
At a glance
- Originator Thallia Pharmaceuticals
- Class
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 20 Jul 1999 Discontinued-Preclinical for Atherosclerosis in France (Unknown route)
- 30 Jun 1998 New profile
- 30 Jun 1998 Preclinical development for Atherosclerosis in France (Unknown route)